Chagas Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Chagas Disease Market Outlook

Thelansis’s “Chagas Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chagas Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chagas Disease Overview

Chagas disease, also known as American trypanosomiasis, is a zoonotic illness caused by the parasite Trypanosoma cruzi. The disease is primarily transmitted by the reduviid bug, commonly called the kissing bug or triatomine bug. Transmission occurs through contact with the bug’s contaminated feces or urine. The parasite enters the body through mucous membranes or open bite wounds. The infective trypomastigote form is most concentrated in the feces of infected reduviid bugs. Alternate routes of transmission include: – Vertical transmission from mother to fetus, resulting in congenital Chagas disease – Organ transplantation – Transfusion of blood and blood products Upon entering the body through a wound or mucous membrane, the infectious trypomastigote can be found in the bloodstream plasma. The amastigote stage of the parasite resides within pseudocysts located in muscle or nerve cells. The parasite targets the myocardium and myenteric plexus of the gastrointestinal tract, where it multiplies through binary fission. The disease progresses through three phases: acute, indeterminate, and chronic. During the acute phase, symptoms can manifest shortly after infection and persist for approximately two months. Chronic infections can endure for many years. It can be treated using medications like nifurtimox and benznidazole, which exhibit over 80% effectiveness during the acute phase. However, they have no impact on the amastigote stage. Management of the chronic phase relies on supportive therapy tailored to the affected organ system. Unfortunately, there is currently no vaccine available for this disease. Prevention methods involve education, improved housing conditions, vector control using bed nets, and screening of blood donations and children in regions where the disease is prevalent.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2024–2034)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Chagas Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Comments

Post a Comment